- Home
- ALLE vs HOLX Comparison
ALLE vs HOLX Comparison
Compare ALLE & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLE | HOLX |
|---|---|---|
| Founded | 2013 | 1985 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medical Electronics |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 16.6B |
| IPO Year | N/A | 1990 |
Fundamental Metrics
Financial Performance| Metric | ALLE | HOLX |
|---|---|---|
| Price | $159.24 | $74.98 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 9 | 15 |
| Target Price | ★ $172.22 | $79.64 |
| AVG Volume (30 Days) | 787.1K | ★ 3.0M |
| Earning Date | 10-23-2025 | 11-03-2025 |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | ★ 13.70 | N/A |
| EPS | ★ 7.39 | 2.49 |
| Revenue | $3,979,700,000.00 | ★ $4,100,500,000.00 |
| Revenue This Year | $10.07 | $6.69 |
| Revenue Next Year | $6.53 | $5.74 |
| P/E Ratio | ★ $21.53 | $30.11 |
| Revenue Growth | ★ 6.87 | 1.74 |
| 52 Week Low | $116.57 | $51.90 |
| 52 Week High | $180.68 | $80.31 |
Technical Indicators
Market Signals| Indicator | ALLE | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 35.06 | 67.93 |
| Support Level | $163.27 | $74.55 |
| Resistance Level | $167.01 | $75.12 |
| Average True Range (ATR) | 3.10 | 0.28 |
| MACD | 0.01 | -0.14 |
| Stochastic Oscillator | 2.11 | 78.92 |
Price Performance
Historical ComparisonAbout ALLE Allegion plc
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.
About HOLX Hologic Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.